Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Food Funct ; 14(9): 4173-4182, 2023 May 11.
Article in English | MEDLINE | ID: mdl-37066543

ABSTRACT

Research on new strategies to regulate glucose homeostasis to prevent or manage type 2 diabetes is a critical challenge. Several studies have shown that protein-rich diets could improve glucose homeostasis. Whey protein hydrolysis allows the release of amino acids and bioactive peptides, which exert numerous well-documented bioactivities. This study evaluates and compares the hypoglycemic potential of a whey protein hydrolysate and a whey protein isolate after static in vitro simulated gastrointestinal digestion (SGID) using the INFOGEST protocol. The peptide molecular mass distributions of the digested samples were evaluated by size exclusion chromatography and show that after digestion, the whey hydrolysate is significantly more hydrolyzed. After SGID, the whey protein hydrolysate induces a significative greater secretion of GLP-1 after two hours of contact with the enteroendocrine STC-1 cell line than the whey protein after isolation. In addition, the digested whey hydrolysate increases preproglucagon (GCG) and pro-convertase-1 (PCSK1) expression. The digested hydrolysate also inhibits the DPP-IV activity after an intestinal barrier passage challenge using a Caco-2/HT29-MTX mixed-cell model. Our results highlight that the prehydrolysis of whey proteins modify the intestinal peptidome, leading to a potentially greater hypoglycemic effect. This study confirms the previously observed in vitro hypoglycemic effect of this hydrolysate and evidences the beneficial impact of the industrial hydrolysis process.


Subject(s)
Diabetes Mellitus, Type 2 , Humans , Whey Proteins/chemistry , Diabetes Mellitus, Type 2/drug therapy , Caco-2 Cells , Protein Hydrolysates/pharmacology , Protein Hydrolysates/chemistry , Hypoglycemic Agents/pharmacology , Peptides/pharmacology , Homeostasis , Glucose
2.
Int J Mol Sci ; 23(15)2022 Jul 28.
Article in English | MEDLINE | ID: mdl-35955493

ABSTRACT

Dipeptidyl-peptidase IV (DPP-IV) plays an essential role in glucose metabolism by inactivating incretins. In this context, food-protein-derived DPP-IV inhibitors are promising glycemic regulators which may act by preventing the onset of type 2 diabetes in personalized nutrition. In this study, the DPP-IV-inhibitory potential of seven proteins from diverse origins was compared for the first time in vitro and in vivo in rat plasma after the intestinal barrier (IB) passage of the indigested proteins. The DPP-IV-inhibitory potentials of bovine hemoglobin, caseins, chicken ovalbumin, fish gelatin, and pea proteins were determined in rat plasma thirty minutes after oral administration. In parallel, these proteins, together with bovine whey and gluten proteins, were digested using the harmonized INFOGEST protocol adapted for proteins. The DPP-IV half-maximal inhibitory concentration (IC50) was determined in situ using Caco-2 cells. The DPP-IV-inhibitory activity was also measured after IB passage using a Caco2/HT29-MTX mixed-cell model. The peptide profiles were analyzed using reversed-phase high-performance liquid chromatography tandem mass spectrometry (RP-HPLC-MS/MS) with MS data bioinformatics management, and the IC50 of the identified peptides was predicted in silico. The in vitro and in vivo DPP-IV-inhibitory activity of the proteins differed according to their origin. Vegetable proteins and hemoglobin yielded the highest DPP-IV-inhibitory activity in vivo. However, no correlation was found between the in vivo and in vitro results. This may be partially explained by the differences between the peptidome analysis and the in silico predictions, as well as the study complexity.


Subject(s)
Diabetes Mellitus, Type 2 , Dipeptidyl-Peptidase IV Inhibitors , Animals , Caco-2 Cells , Digestion , Dipeptidyl Peptidase 4/metabolism , Dipeptidyl-Peptidase IV Inhibitors/chemistry , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Humans , Peptides/chemistry , Rats , Tandem Mass Spectrometry
3.
Food Res Int ; 157: 111360, 2022 07.
Article in English | MEDLINE | ID: mdl-35761622

ABSTRACT

Milk and dairy products are significant sources of proteins and peptides impacting human health. In this way, the interest in CPPs, bioactive phosphorylated peptides resulting from the hydrolysis of caseins, has grown in the past years. CPPs were mainly studied for their capacity to chelate and increase the bioavailability of essential minerals involved in multiple physiological processes. Moreover, CPPs harbour interesting antioxidant and anti-inflammatory properties. Recent in vivo and in vitro studies demonstrated that these different roles are strongly linked to the intrinsic properties of CPPs and CPP concentrate preparations. This review first comments on the different methods of CPP analytical characterization, focusing on recent techniques. Then, the CPP release occurring during the gastrointestinal digestion was reviewed, followed by the different CPP obtention processes and their impact on their physicochemical characteristics. Finally, the different bioactive roles attributed to CPPs, including mineral chelating properties, are discussed. We show that CPPs have a promising role in treating various pathologies, notably to compensate for deficiencies in certain nutrients and an anti-oxidant and anti-inflammatory role. Nevertheless, the mechanisms by which CPPs exert their role remain to be elucidated, and this requires precise characterization of CPPs. This work highlights the key parameters to be considered to study and produce CPPs and the different ways to be investigated in the future to elucidate their roles in vivo and characterize their potential for human health.


Subject(s)
Caseins , Phosphopeptides , Animals , Biological Availability , Caseins/chemistry , Humans , Milk/chemistry , Minerals/analysis , Phosphopeptides/chemistry
4.
Front Nutr ; 8: 769773, 2021.
Article in English | MEDLINE | ID: mdl-35127780

ABSTRACT

Several studies have demonstrated that high protein diets improve glucose homeostasis. Nevertheless, the mechanisms underlying this effect remain elusive. This exploratory study aims to screen and compare the acute effects of dietary proteins from different sources on intestinal glucose absorption. Six dietary proteins from various sources were thus selected and digested thanks to the INFOGEST static gastrointestinal digestion protocol. The digested proteins were able to decrease intestinal glucose absorption in vitro and ex vivo. Moreover, acute ingestion of casein and fish gelatin led to improved glucose tolerance in Wistar rats without significant effect on insulin secretion. In parallel, GLUT2 mRNA expression in enterocytes was decreased following short-term incubation with some of the digested proteins. These results strengthen the evidence that digested protein-derived peptides and amino acids are key regulators of glucose homeostasis and highlight their role in intestinal glucose absorption.

5.
Nutrients ; 12(12)2020 Dec 05.
Article in English | MEDLINE | ID: mdl-33291464

ABSTRACT

The gastrointestinal digestion of food proteins can generate peptides with a wide range of biological activities. In this study, we screened various potential bioactivities generated by plant-based proteins. Whey protein as an animal protein reference, five grades of pea protein, two grades of wheat protein, and potato, fava bean, and oat proteins were submitted to in vitro SGID. They were then tested in vitro for several bioactivities including measures on: (1) energy homeostasis through their ability to modulate intestinal hormone secretion, to inhibit DPP-IV activity, and to interact with opioid receptors; (2) anti-hypertensive properties through their ability to inhibit ACE activity; (3) anti-inflammatory properties in Caco-2 cells; (4) antioxidant properties through their ability to inhibit production of reactive oxygen species (ROS). Protein intestinal digestions were able to stimulate intestinal hormone secretion by enteroendocrine cells, to inhibit DPP-IV and ACE activities, to bind opioid receptors, and surprisingly, to decrease production of ROS. Neither pro- nor anti-inflammatory effects have been highlighted and some proteins lost their pro-inflammatory potential after digestion. The best candidates were pea, potato, and fava bean proteins.


Subject(s)
Digestion/drug effects , Plant Proteins/metabolism , Plant Proteins/pharmacology , Animals , Antioxidants , Caco-2 Cells , Cytokines/metabolism , Diet, Vegetarian , Dipeptidyl Peptidase 4/drug effects , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Fabaceae , Glucagon-Like Peptide 1 , Humans , Inflammation , Interleukin-8 , Intestines , Mass Screening , Peptides/chemistry , Peptidyl-Dipeptidase A/drug effects , Plant Proteins/chemistry , Protein Hydrolysates , Receptors, Opioid , Whey Proteins
6.
J Agric Food Chem ; 66(25): 6439-6449, 2018 Jun 27.
Article in English | MEDLINE | ID: mdl-29873488

ABSTRACT

The objectives of this work are to address the prebiotic effects of chicory ( Cichorium intybus) together with its possible role in appetite control. We compared nine chicory genotypes in order to determine if variations in the content of metabolites in the roasted roots would lead to modifications in release of satiety hormones and in composition of gut microbiota. To this aim, a 5-week dietary-intervention study was achieved using mice fed with distinct chicory-based preparations. A 16S rRNA gene-based metagenetic analysis of fecal microbiota was performed. In vitro gastrointestinal digestions were performed in order to study the effect of chicory intestinal digests on gut hormone regulation in enteroendocrine cells. Firmicutes/Bacteroidetes ratio and gut bacterial groups, such as Alloprevotella, Blautia, Alistipes, and Oscillibacter, were found to be modulated by chicory. On the other hand, CCK and GLP-1 satiety hormones were demonstrated to be significantly increased by chicory in vitro.


Subject(s)
Appetite Regulation/drug effects , Cichorium intybus/chemistry , Plant Extracts/pharmacology , Prebiotics/analysis , Animals , Bacteria/classification , Bacteria/genetics , Bacteria/isolation & purification , Cichorium intybus/genetics , Cichorium intybus/metabolism , Digestion/drug effects , Gastrointestinal Microbiome/drug effects , Gastrointestinal Tract/metabolism , Gastrointestinal Tract/microbiology , Mice , Plant Extracts/metabolism
7.
Acta Diabetol ; 54(2): 191-199, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27796655

ABSTRACT

AIMS: The dyslipidemia associated with type 2 diabetes is a major risk factor for the development of atherosclerosis. Trans-intestinal cholesterol excretion (TICE) has recently been shown to contribute, together with the classical hepatobiliary route, to fecal cholesterol excretion and cholesterol homeostasis. The aim of this study was to develop an in vitro cell model to investigate enterocyte-related processes of TICE. METHODS: Differentiated Caco-2/TC7 cells were grown on transwells and incubated basolaterally (blood side) with human plasma and apically (luminal side) with lipid micelles. Radioactive and fluorescent cholesterol tracers were used to investigate cholesterol uptake at the basolateral membrane, intracellular distribution and apical excretion. RESULTS: Our results show that cholesterol is taken up at the basolateral membrane, accumulates intracellularly as lipid droplets and undergoes a cholesterol acceptor-facilitated and progressive excretion through the apical membrane of enterocytes. The overall process is abolished at 4 °C, suggesting a biologically active phenomenon. Moreover, this trans-enterocytic retrograde cholesterol transport displays some TICE features like modulation by PCSK9 and an ABCB1 inhibitor. Finally, we highlight the involvement of microtubules in the transport of plasma cholesterol from basolateral to apical pole of enterocytes. CONCLUSIONS: The human Caco-2/TC7 cell line appears a good in vitro model to investigate the enterocytic molecular mechanisms of TICE, which may help to identify intestinal molecular targets to enhance reverse cholesterol transport and fight against dyslipidemia.


Subject(s)
Atherosclerosis/complications , Cholesterol/metabolism , Diabetes Mellitus, Type 2/complications , Dyslipidemias/metabolism , Enterocytes/metabolism , Exocytosis , Caco-2 Cells , Dyslipidemias/etiology , Humans
8.
Gastroenterology ; 150(3): 650-8, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26602218

ABSTRACT

BACKGROUND & AIMS: Reducing postprandial triglyceridemia may be a promising strategy to lower the risk of cardiovascular disorders associated with obesity and type 2 diabetes. In enterocytes, scavenger receptor class B, type 1 (SR-B1, encoded by SCARB1) mediates lipid-micelle sensing to promote assembly and secretion of chylomicrons. The nuclear receptor subfamily 1, group H, members 2 and 3 (also known as liver X receptors [LXRs]) regulate genes involved in cholesterol and fatty acid metabolism. We aimed to determine whether intestinal LXRs regulate triglyceride absorption. METHODS: C57BL/6J mice were either fed a cholesterol-enriched diet or given synthetic LXR agonists (GW3965 or T0901317). We measured the production of chylomicrons and localized SR-B1 by immunohistochemistry. Mechanisms of postprandial triglyceridemia and SR-B1 regulation were studied in Caco-2/TC7 cells incubated with LXR agonists. RESULTS: In mice and in the Caco-2/TC7 cell line, LXR agonists caused localization of intestinal SR-B1 from apical membranes to intracellular organelles and reduced chylomicron secretion. In Caco-2/TC7 cells, LXR agonists reduced SR-B1-dependent lipidic-micelle-induced Erk phosphorylation. LXR agonists also reduced intracellular trafficking of the apical apolipoprotein B pool toward secretory compartments. LXR reduced levels of SR-B1 in Caco-2/TC7 cells via a post-transcriptional mechanism that involves microRNAs. CONCLUSION: In Caco-2/TC7 cells and mice, intestinal activation of LXR reduces the production of chylomicrons by a mechanism dependent on the apical localization of SR-B1.


Subject(s)
Intestinal Absorption , Intestinal Mucosa/metabolism , Jejunum/metabolism , Orphan Nuclear Receptors/metabolism , Scavenger Receptors, Class B/metabolism , Triglycerides/metabolism , Animals , Apolipoprotein B-100/metabolism , Apolipoproteins B/metabolism , Benzoates/pharmacology , Benzylamines/pharmacology , Caco-2 Cells , Cholesterol, Dietary/metabolism , Chylomicrons/metabolism , DEAD-box RNA Helicases/deficiency , DEAD-box RNA Helicases/genetics , Down-Regulation , Humans , Hydrocarbons, Fluorinated/pharmacology , Intestinal Absorption/drug effects , Intestinal Mucosa/drug effects , Jejunum/drug effects , Liver X Receptors , Male , Mice, Inbred C57BL , Mice, Knockout , MicroRNAs/genetics , MicroRNAs/metabolism , Orphan Nuclear Receptors/agonists , Protein Transport , RNA Interference , Ribonuclease III/deficiency , Ribonuclease III/genetics , Scavenger Receptors, Class B/deficiency , Scavenger Receptors, Class B/genetics , Signal Transduction , Sulfonamides/pharmacology , Transcription, Genetic , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...